China approves Pfizer's GLP-1 drug for weight management, intensifying market competition
Source: SeekingAlpha
2026-03-06 02:27:55 ET
More on Pfizer
- Pfizer: Obesity Hype And Vaccine Policy Shocks
- Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
- Pfizer's Quiet Cash Comeback
- Pfizer-backed Priovant wins FDA priority review for lead asset
- FDA reportedly eyeing staff bonuses to accelerate drug reviews
Read the full article on Seeking Alpha
For further details see:
China approves Pfizer’s GLP-1 drug for weight management, intensifying market competition
Innovent Biologics Inc ADR
NASDAQ: IVBIY
IVBIY Trading
-4.51% G/L:
$40 Last:
1,006 Volume:
$41.89 Open:
IVBIY Latest News
January 26, 2026 07:00:00 pm
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
January 08, 2026 07:00:00 pm
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
